Matías Marín Falco

Matías Marín Falco

Auto-generated profile, based on publicly available information

Matías Marín Falco

Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
AHAriel A. Hippen
Ariel A. Hippen
MFMatias M. Falco
Matias M. Falco
LWLukas M. Weber
Lukas M. Weber
EEErdogan Pekcan Erkan
Erdogan Pekcan Erkan
KZKaiyang Zhang
Kaiyang Zhang
SHStephanie C. Hicks
Stephanie C. Hicks
Single-cell RNA-sequencing (scRNA-seq) has made it possible to profile gene expression in tissues at high resolution. An important preprocessing step prior to performing downstream analyses is to identify and remove cells with poor or degraded sample quality using quality control (QC) metrics. Two widely used QC metrics to identify a ‘low-quality’ cell are (i) if the cell includes a high proportion of reads that map to mitochondrial DNA (mtDNA) encoded genes and (ii) if a small number of genes are detected. Current best practices use these QC metrics independently with either arbitrary, uniform thresholds (e.g. 5%) or biological context-dependent (e.g. species) thresholds, and fail to jointly model these metrics in a data-driven manner. Current practices are often overly stringent and especially untenable on certain types of tissues, such as archived tumor tissues, or tissues associated with mitochondrial function, such as kidney tissue [1]. We propose a data-driven QC metric (miQC) that jointly models both the proportion of reads mapping to mtDNA genes and the number of detected genes with mixture models in a probabilistic framework to predict the low-quality cells in a given dataset. We demonstrate how our QC metric easily adapts to different types of single-cell datasets to remove low-quality cells while preserving high-quality cells that can be used for downstream analyses. Our software package is available athttps://bioconductor.org/packages/miQC.

17 July 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
TSTito A. Sandoval
Tito A. Sandoval
CSCamilla Salvagno
Camilla Salvagno
CCChang-Suk Chae
Chang-Suk Chae
Deepika AwasthiDeepika Awasthi
Deepika Awasthi
PGPaolo Giovanelli
Paolo Giovanelli
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz
Iron accumulation in tumors contributes to disease progression and chemoresistance. Although targeting this process can influence various hallmarks of cancer, the immunomodulatory effects of iron chelation in the tumor microenvironment are unknown. Here, we report that treatment with deferiprone, an FDA-approved iron chelator, unleashes innate immune responses that restrain ovarian cancer. Deferiprone reprogrammed ovarian cancer cells toward an immunostimulatory state characterized by the production of type-I IFN and overexpression of molecules that activate NK cells. Mechanistically, these effects were driven by innate sensing of mitochondrial DNA in the cytosol and concomitant activation of nuclear DNA damage responses triggered upon iron chelation. Deferiprone synergized with chemotherapy and prolonged the survival of mice with ovarian cancer by bolstering type-I IFN responses that drove NK cell-dependent control of metastatic disease. Hence, iron chelation may represent an alternative immunotherapeutic strategy for malignancies that are refractory to current T-cell–centric modalities. Significance: This study uncovers that targeting dysregulated iron accumulation in ovarian tumors represents a major therapeutic opportunity. Iron chelation therapy using an FDA-approved agent causes immunogenic stress responses in ovarian cancer cells that delay metastatic disease progression and enhance the effects of first-line chemotherapy. See related commentary by Bell and Zou, p. 1771

7 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JDJun Dai
Jun Dai
SZShuyu Zheng
Shuyu Zheng
MFMatías M. Falco
Matías M. Falco
JBJie Bao
Jie Bao
JEJohanna Eriksson
Johanna Eriksson
AVAnna Vähärautio
Anna Vähärautio
Exploring non-genetic evolution of cell states during cancer treatments has become attainable by recent advances in lineage-tracing methods. However, transcriptional changes that drive cells into resistant fates may be subtle, necessitating high resolution analysis. Here, we present ReSisTrace that uses shared transcriptomic features of sister cells to predict the states priming treatment resistance. Applying ReSisTrace in ovarian cancer cells perturbed with olaparib, carboplatin or natural killer (NK) cells reveals pre-resistant phenotypes defined by proteostatic and mRNA surveillance features, reflecting traits enriched in the upcoming subclonal selection. Furthermore, we show that DNA repair deficiency renders cells susceptible to both DNA damaging agents and NK killing in a context-dependent manner. Finally, we leverage the obtained pre-resistance profiles to predict and validate small molecules driving cells to sensitive states prior to treatment. In summary, ReSisTrace resolves pre-existing transcriptional features of treatment vulnerability, facilitating both molecular patient stratification and discovery of synergistic pre-sensitizing therapies.

9 February 2026 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
Fernando Perez VillatoroFernando Perez Villatoro
Fernando Perez Villatoro
ASAleksandra Shabanova
Aleksandra Shabanova
LWLilian van Wagensveld
Lilian van Wagensveld
AJAda Junquera
Ada Junquera
INIga Niemiec
Iga Niemiec
AFAnniina Färkkilä
Anniina Färkkilä
The tumor microenvironment in high-grade serous ovarian carcinoma (HGSC) is a complex network of malignant–host cell interactions, yet its orchestration remains poorly understood. We present a single-cell spatial atlas of metastatic HGSC from 280 patients, integrating high-dimensional imaging and molecular profiling. Analyzing 929 single-cell maps, we identify spatial domains with diverse cell compositions and show that immune cell coinfiltration at the tumor–stroma interface affects clinical outcomes. Using Cell Feature Importance Identification by RAndom forest (CEFIIRA), we find that tumor cell MHC class II (MHCII) expression is a key predictor of prolonged survival. Validation with deconvoluted single-cell and two distinct spatial transcriptomic datasets, along with immunopeptidomic analysis, confirms that MHCII expression correlates with immune activation, antigen presentation, and T-cell receptor clonality. Using a patient-derived immuno-oncology platform, we demonstrate that tumor MHCII expression associates with increased CD8+ T-cell cytotoxicity after PD-1 blockade, whereas blocking MHCII inhibits this activation. Our atlas offers new insights into immune activation, potentially improving patient stratification in HGSC. Significance: This study delivers the first large-scale single-cell spatial atlas of HGSC, revealing how tumor–immune organization shapes outcomes. We identify tumor-intrinsic MHCII as a key driver of local immune activation and immunotherapy responsiveness, providing a mechanistic biomarker that can immediately inform improved patient stratification and therapeutic decision-making in ovarian cancer. See related commentary by Conejo-Garcia and Dangaj Laniti, p. 1041

20 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ILInga-Maria Launonen
Inga-Maria Launonen
EEErdogan Pekcan Erkan
Erdogan Pekcan Erkan
INIga Niemiec
Iga Niemiec
AJAda Junquera
Ada Junquera
MHMaría Hincapié-Otero
María Hincapié-Otero
AFAnniina Färkkilä
Anniina Färkkilä
Summary: To uncover the intricate, chemotherapy-induced spatiotemporal remodeling of the tumor microenvironment, we conducted integrative spatial and molecular characterization of 97 high-grade serous ovarian cancer (HGSC) samples collected before and after chemotherapy. Using single-cell and spatial analyses, we identify increasingly versatile immune cell states, which form spatiotemporally dynamic microcommunities at the tumor-stroma interface. We demonstrate that chemotherapy triggers spatial redistribution and exhaustion of CD8+ T cells due to prolonged antigen presentation by macrophages, both within interconnected myeloid networks termed “Myelonets” and at the tumor stroma interface. Single-cell and spatial transcriptomics identifies prominent TIGIT-NECTIN2 ligand-receptor interactions induced by chemotherapy. Using a functional patient-derived immuno-oncology platform, we show that CD8+T-cell activity can be boosted by combining immune checkpoint blockade with chemotherapy. Our discovery of chemotherapy-induced myeloid-driven spatial T-cell exhaustion paves the way for novel immunotherapeutic strategies to unleash CD8+ T-cell-mediated anti-tumor immunity in HGSC.

21 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
WSWojciech Senkowski
Wojciech Senkowski
LGLaura Gall-Mas
Laura Gall-Mas
MFMatias Marin Falco
Matias Marin Falco
YLYilin Li
Yilin Li
KLKari Lavikka
Kari Lavikka
KWKrister Wennerberg
Krister Wennerberg
The broad research use of organoids from high-grade serous ovarian carcinoma (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (55% vs. 23-38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.